Arthur Allen is a journalist at various esteemed publications including The Oregonian and NBC News. He focuses on themes related to medicine and healthcare, covering topics such as the coronavirus, FDA regulations, and nutrition, while also exploring alternative medicine and wellness. His work has been featured in numerous outlets, including CNN, NPR, and Fortune.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Arthur Allen focuses extensively on healthcare and pharmaceutical topics, specifically relating to government announcements and legal policy regulation within the United States. He seems particularly interested in stories related to new medical tests, drug markets such as biosimilars, and their impact on patients.
Given his focus on government announcements and citing data, he may be receptive to pitches that offer insights into how specific policies or regulations will affect the healthcare industry. Additionally, experts who can provide analysis of data trends in the pharmaceutical sector could capture his interest.
If you have expertise in any of these areas or if your organization has insights into how specific policies might shape the future of healthcare in the U.S., Arthur Allen would likely be an ideal contact for outreach.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Arthur Allen
Mark Cuban speaks at a panel on Dec. 3 in San Francisco. Cuban says he has told hundreds of Fortune 500 executives, in one-on-one meetings and in groups, that they are overpaying on drug benefit plans skewed to fatten the wallets of big pharmacy benefit managers. (Jon Kopaloff/Getty Images for WIRED)
Dr. Josie Tenore and Paul Hinds were introduced by a mutual friend in 2017 and hadn’t been going out long when she laid down the law: He had to get a physical. “I don’t date people who don’t take care of their health,” said Tenore, who practices cosmetic dermatology and functional medicine in suburb...
As criticism of pharmacy benefit managers heats up, fear of lawsuits is driving some big employers to drop the “Big Three” PBMs — or force them to change.
The availability of safe, effective covid vaccines less than a year into the pandemic marked a high point in the 300-year history of vaccination, seemingly heralding an age of protection against infectious diseases.
By: Arthur Allen
Ann Lewandowski knows all about pharmacy benefit managers, or PBMs, the companies that shape the U.S. drug market.
By: Arthur Allen
Ann Lewandowski knows all about pharmacy benefit managers, or PBMs, the companies that shape the U.S. drug market.
By: Arthur Allen
Ann Lewandowski knows all about pharmacy benefit managers, or PBMs, the companies that shape the U.S. drug market.
By: Arthur Allen
Ann Lewandowski knows all about pharmacy benefit managers, or PBMs, the companies that shape the U.S. drug market. Her job, as a policy advocate at drugmaker Johnson & Johnson, was
By: Arthur Allen
Dissatisfaction with the status quo and fear of liability are pushing employers to switch from the “Big Three” PBMs to “transparent PBMs.”
By: Arthur Allen
Ann Lewandowski knows all about pharmacy benefit managers, or PBMs, the companies that shape the U.S. drug market. Her job, as a policy advocate at drugmaker Johnson & Johnson, was to tell patient and physician groups about the PBMs' role in high drug prices.
(833) 317-6278 
